Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.

Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio, with significant contributions from rare disease treatments and biosimilars. Financially robust, Amgen ...

Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual ...

But shares of Amgen fell about 5% on Tuesday, as the results appear to be at the lower end of Wall Street's lofty expectations for the drug. Ahead of the data, several analysts said they wanted ...

Shares of biotech company Amgen (NASDAQ:AMGN) jumped 5.3% in the morning session after the company reported strong fourth-quarter results. Amgen exceeded analysts' revenue expectations this ...

Amgen Inc.’s stock closed down 4.8% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed up to 20% average weight loss at 52 weeks. Analysts were ...